News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
252,530 Results
Type
Article (5896)
Company Profile (28)
Press Release (246606)
Multimedia
Podcasts (2)
Webinars (5)
Section
Business (87679)
Career Advice (472)
Deals (16484)
Drug Delivery (9)
Drug Development (21242)
Employer Resources (32)
FDA (4052)
Job Trends (4556)
News (129784)
Policy (8422)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (337)
Accelerated approval (8)
Adcomms (4)
Allergies (15)
Alliances (16224)
ALS (42)
Alzheimer's disease (378)
Antibody-drug conjugate (ADC) (48)
Approvals (4163)
Artificial intelligence (95)
Autoimmune disease (32)
Automation (5)
Bankruptcy (107)
Best Places to Work (3390)
Biosimilars (33)
Biotechnology (30)
Bladder cancer (39)
Brain cancer (10)
Breast cancer (144)
Cancer (1025)
Cardiovascular disease (68)
Career advice (404)
Career pathing (3)
CAR-T (67)
CDC (2)
Cell therapy (178)
Cervical cancer (5)
Clinical research (18514)
Collaboration (393)
Compensation (383)
Complete response letters (9)
COVID-19 (461)
CRISPR (13)
C-suite (358)
Cystic fibrosis (30)
Data (1476)
Denatured (1)
Depression (24)
Diabetes (86)
Diagnostics (2337)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (14)
Drug discovery (48)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (38)
Earnings (44775)
Editorial (5)
Employer branding (6)
Employer resources (34)
Events (41985)
Executive appointments (448)
FDA (4845)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (399)
Gene editing (25)
Generative AI (5)
Gene therapy (102)
GLP-1 (164)
Government (519)
Guidances (203)
Healthcare (5577)
HIV (10)
Huntington's disease (5)
IgA nephropathy (18)
Immunology and inflammation (41)
Immuno-oncology (8)
Indications (16)
Infectious disease (493)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (37)
Interviews (57)
IPO (8473)
IRA (3)
Job creations (1259)
Job search strategy (366)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (113)
Leadership (5)
Legal (2678)
Liver cancer (21)
Longevity (4)
Lung cancer (105)
Lymphoma (75)
Machine learning (4)
Management (11)
Manufacturing (155)
MASH (50)
Medical device (4368)
Medtech (4381)
Mergers & acquisitions (8474)
Metabolic disorders (226)
Multiple sclerosis (22)
NASH (6)
Neurodegenerative disease (65)
Neuropsychiatric disorders (14)
Neuroscience (654)
NextGen: Class of 2026 (1792)
Non-profit (793)
Now hiring (5)
Obesity (89)
Opinion (33)
Ovarian cancer (26)
Pain (33)
Pancreatic cancer (51)
Parkinson's disease (52)
Partnered (12)
Patents (67)
Patient recruitment (105)
Peanut (6)
People (27116)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase 1 (5502)
Phase 2 (8135)
Phase 3 (6396)
Pipeline (2046)
Policy (17)
Postmarket research (658)
Preclinical (2176)
Press Release (67)
Prostate cancer (63)
Psychedelics (5)
Radiopharmaceuticals (126)
Rare diseases (189)
Real estate (2025)
Recruiting (9)
Regulatory (6096)
Reports (18)
Research institute (359)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (4)
RSV (2)
Schizophrenia (57)
Series A (58)
Series B (56)
Service/supplier (2)
Sickle cell disease (11)
Special edition (1)
Spinal muscular atrophy (35)
Sponsored (6)
Startups (1132)
State (1)
Stomach cancer (1)
Supply chain (17)
Tariffs (7)
The Weekly (1)
Vaccines (107)
Venture capital (10)
Weight loss (30)
Women's health (7)
Date
Last 7 days (169)
Last 30 days (602)
Last 365 days (9898)
2026 (879)
2025 (10076)
2024 (12204)
2023 (14503)
2022 (20418)
2021 (21838)
2020 (19696)
2019 (14289)
2018 (10999)
2017 (10865)
2016 (9993)
2015 (13151)
2014 (10359)
2013 (8347)
2012 (9039)
2011 (9442)
2010 (9255)
Location
Africa (201)
Alabama (20)
Alaska (2)
Arizona (83)
Arkansas (1)
Asia (12514)
Australia (1760)
California (3670)
Canada (1755)
China (173)
Colorado (152)
Connecticut (168)
Delaware (76)
Europe (26903)
Florida (564)
Georgia (76)
Idaho (24)
Illinois (168)
India (15)
Indiana (139)
Iowa (9)
Japan (178)
Kansas (37)
Kentucky (18)
Louisiana (8)
Maine (51)
Maryland (359)
Massachusetts (2905)
Michigan (143)
Minnesota (231)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (14)
Nevada (53)
New Hampshire (27)
New Jersey (1230)
New Mexico (8)
New York (924)
North Carolina (517)
North Dakota (4)
Northern California (1915)
Ohio (117)
Oklahoma (8)
Oregon (6)
Pennsylvania (687)
Puerto Rico (2)
Rhode Island (19)
South America (311)
South Carolina (17)
Southern California (1344)
Tennessee (71)
Texas (561)
United States (13318)
Utah (114)
Virginia (85)
Washington D.C. (17)
Washington State (307)
West Virginia (2)
Wisconsin (71)
Wyoming (2)
252,530 Results for "intelgenx corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
IntelGenx Corp. announced positive results from a proof-of-concept study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats.
February 5, 2024
·
4 min read
Press Releases
IntelGenx Announces Rebranding to Nualtis, Signaling Strategic Evolution and Renewed Vision
June 11, 2025
·
2 min read
Business
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the three- and twelve-month periods ended December 31, 2023.
March 21, 2024
·
7 min read
Press Releases
Profound Medical Corp. Announces Closing of Private Placement
December 30, 2025
·
5 min read
Press Releases
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
January 21, 2026
·
7 min read
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.
April 5, 2024
·
3 min read
Press Releases
Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
January 15, 2026
·
5 min read
Drug Development
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
April 8, 2024
·
5 min read
Press Releases
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
January 23, 2026
·
6 min read
IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Corp. announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share, for a maximum Offering amount of $20,000,000.
February 20, 2024
·
5 min read
1 of 25,253
Next